Evaluation of the Effects of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Fulvestrant; Letrozole
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics
Most Recent Events
- 27 Feb 2025 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
- 27 Feb 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
- 12 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.